Почетна › Рак дојке › Nebraska › Omaha
Kliničke studije za Рак дојке u gradu Omaha, NE
23 studija za Рак дојке traži učesnike na lokacijama u gradu Omaha i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
A Study Evaluating the Safety of Inavolisib and Fulvestrant With or Without Palbociclib in Participants With Advanced Breast Cancer (ABC) and Type 2 Diabetes
Тражи се учесникФаза 2
- Nebraska Cancer Specialists, Omaha
Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
Тражи се учесникФаза 1/2
- Research Facility, Omaha
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Тражи се учесникФаза 2
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists, Omaha
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Тражи се учесникФаза 1/2
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Тражи се учесникФаза 3
- Nebraska Cancer Specialists, Omaha
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Тражи се учесникФаза 3
- Nebraska Cancer Specialists, Omaha
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Тражи се учесникФаза 3
- Nebraska Medicine-Village Pointe, Omaha
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- и још 3
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
Тражи се учесникФаза 1
- Nebraska Cancer Specialists, Omaha
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Тражи се учесникФаза 3
- Paradigm Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Тражи се учесникФаза 2
- Nebraska Cancer Specialists, Omaha
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Тражи се учесникФаза 1/2
- Nebraska Cancer Specialists, Omaha
ERAS Protocols in Breast Conserving Surgery
Тражи се учесник
- University of Nebraska Medical Center, Omaha
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Тражи се учесникФаза 3
- Research Site, Omaha
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Тражи се учесникФаза 3
- Nebraska Cancer Specialists, Omaha
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Тражи се учесникФаза 3
- Nebraska Cancer Specialists, Omaha
- Nebraska Medicine - University of Nebraska Medical Center, Omaha
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Тражи се учесникФаза 2
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha
Integrated Cancer Repository for Cancer Research
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
- Methodist Estabrook Cancer Center, Omaha
- Nebraska Methodist Health System, Omaha
- University of Nebraska Medical Center, Omaha
- и још 1
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Тражи се учесникФаза 1
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Тражи се учесникФаза 3
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9 ми удаљено
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Тражи се учесникОпсервациона студија
- Massive Bio SYNERGY-AI site, Omaha
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
Тражи се учесникФаза 1
- Biotheryx Investigative Site, Omaha
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Тражи се учесникОпсервациона студија
- Nebraska Methodist, Omaha
Studije za Рак дојке u drugim gradovima
- New York City, NY144 студија
- Houston, TX126 студија
- Boston, MA110 студија
- Nashville, TN78 студија
- Los Angeles, CA73 студија
- Edison, NJ70 студија
- Queens, NY67 студија
- Durham, NC63 студија
- St. Louis, MO63 студија
- Chicago, IL59 студија
- Dallas, TX54 студија
- Philadelphia, PA51 студија
Ostale studije u gradu Omaha
- Рак простате29 студија
- Немалоклетни карцином плућа25 студија
- Рак (све врсте)19 студија
- Колоректални карцином18 студија
- Многи мијелом17 студија
- Рак јајника15 студија
- Рак панкреаса15 студија
- Плоскоклеточни карцином главе и врата15 студија
- Метастатски карцином14 студија
- Не-Ходжкинов лимфом14 студија
- Рак плућа13 студија
- Рак бубрега (карцином бубрежних ћелија)12 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.